Skip to main content

Advertisement

SpringerLink
Log in

Clinical role of additional adjuvant chemotherapy in patients with locally advanced urothelial carcinoma following neoadjuvant chemotherapy and cystectomy

  • Original Article
  • Published:
World Journal of Urology Aims and scope Submit manuscript

Abstract

Purpose

Neoadjuvant chemotherapy (NAC) can downstage invasive bladder cancers prior to radical cystectomy (RC) and improve overall survival. However, the optimal management in patients with persistent non-organ confined disease (pT3–T4 and/or pN+) following RC has not been completely defined. The aim of this study was to describe outcomes associated with the use of adjuvant chemotherapy (AC) in patients with residual non-organ confined cancer at RC following NAC.

Materials and methods

Using data from a high-volume referral institution, pT3–T4 and/or pN+ patients who received NAC and then also RC were identified. Recurrence-free survival (RFS) and cancer-specific survival (CSS) were assessed with Kaplan–Meier analysis.

Results

From 2001 to 2013, 161 patients received NAC and then RC. Eighty-eight pT3–T4 and/or pN+ patients were identified. Twenty-nine (33 %) received AC. Adjuvant chemotherapy in the majority of patients was carboplatin-based (16), followed by cisplatin (8) and other, mainly taxane-containing regimens (5). The median RFS was 17.5 months in the AC and 13.7 months in the non-AC group (p = 0.78). AC remained an insignificant predictor for RFS after adjusting for pT, pN and margin status (HR 0.89, 95 % CI 0.48–1.68]). CSS was 23 and 22 months (p = 0.65) and remained insignificant after adjusting for pathologic confounders.

Conclusions

In our current study population, adjuvant conventional cytotoxic chemotherapy was not associated with significant improvements in RFS or CSS. The choice of AC regimens, and incorporation of newer treatments, may be the key for improving outcomes in this high-risk patient group.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Fairey AS, Daneshmand S, Quinn D, Dorff T, Dorin R, Lieskovsky G, Schuckman A, Cai J, Miranda G, Skinner EC (2013) Neoadjuvant chemotherapy with gemcitabine/cisplatin vs. methotrexate/vinblastine/doxorubicin/cisplatin for muscle-invasive urothelial carcinoma of the bladder: a retrospective analysis from the University of Southern California. Urol Oncol 31(8):1737–1743. doi:10.1016/j.urolonc.2012.07.005

    Article  CAS  PubMed  Google Scholar 

  2. Petrelli F, Coinu A, Cabiddu M, Ghilardi M, Vavassori I, Barni S (2014) Correlation of pathologic complete response with survival after neoadjuvant chemotherapy in bladder cancer treated with cystectomy: a meta-analysis. Eur Urol 65(2):350–357. doi:10.1016/j.eururo.2013.06.049

    Article  PubMed  Google Scholar 

  3. Rosenblatt R, Sherif A, Rintala E, Wahlqvist R, Ullen A, Nilsson S, Malmstrom PU (2012) Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer. Eur Urol 61(6):1229–1238. doi:10.1016/j.eururo.2011.12.010

    Article  PubMed  Google Scholar 

  4. Stenzl A, Cowan NC, De Santis M, Kuczyk MA, Merseburger AS, Ribal MJ, Sherif A, Witjes JA, European Association of U (2011) Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines. Eur Urol 59(6):1009–1018. doi:10.1016/j.eururo.2011.03.023

    Article  CAS  PubMed  Google Scholar 

  5. Grossman HB, Natale RB, Tangen CM, Speights VO, Vogelzang NJ, Trump DL, deVere White RW, Sarosdy MF, Wood DP Jr, Raghavan D, Crawford ED (2003) Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 349(9):859–866. doi:10.1056/NEJMoa022148

    Article  CAS  PubMed  Google Scholar 

  6. Advanced Bladder Cancer Meta-analysis C (2003) Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis. Lancet 361(9373):1927–1934

    Article  Google Scholar 

  7. Advanced Bladder Cancer Meta-analysis C (2005) Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol 48(2):202–205. doi:10.1016/j.eururo.2005.04.006 (discussion 205–206)

    Article  Google Scholar 

  8. International Collaboration of T, Medical Research Council Advanced Bladder Cancer Working P, European Organisation for R, Treatment of Cancer Genito-Urinary Tract Cancer G, Australian Bladder Cancer Study G, National Cancer Institute of Canada Clinical Trials G, Finnbladder, Norwegian Bladder Cancer Study G, Club Urologico Espanol de Tratamiento Oncologico G, Griffiths G, Hall R, Sylvester R, Raghavan D, Parmar MK (2011) International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol 29(16):2171–2177. doi:10.1200/JCO.2010.32.3139

    Article  Google Scholar 

  9. Karakiewicz PI, Shariat SF, Palapattu GS, Gilad AE, Lotan Y, Rogers CG, Vazina A, Gupta A, Bastian PJ, Perrotte P, Sagalowsky AI, Schoenberg M, Lerner SP (2006) Nomogram for predicting disease recurrence after radical cystectomy for transitional cell carcinoma of the bladder. J Urol 176(4 Pt 1):1354–1361. doi:10.1016/j.juro.2006.06.025 (discussion 1361–1352)

    Article  PubMed  Google Scholar 

  10. Stein JP, Lieskovsky G, Cote R, Groshen S, Feng AC, Boyd S, Skinner E, Bochner B, Thangathurai D, Mikhail M, Raghavan D, Skinner DG (2001) Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 19(3):666–675

    CAS  PubMed  Google Scholar 

  11. Madersbacher S, Hochreiter W, Burkhard F, Thalmann GN, Danuser H, Markwalder R, Studer UE (2003) Radical cystectomy for bladder cancer today—a homogeneous series without neoadjuvant therapy. J Clin Oncol 21(4):690–696

    Article  PubMed  Google Scholar 

  12. Freiha F, Reese J, Torti FM (1996) A randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer. J Urol 155(2):495–499 (discussion 499–500)

    Article  CAS  PubMed  Google Scholar 

  13. Stockle M, Meyenburg W, Wellek S, Voges GE, Rossmann M, Gertenbach U, Thuroff JW, Huber C, Hohenfellner R (1995) Adjuvant polychemotherapy of nonorgan-confined bladder cancer after radical cystectomy revisited: long-term results of a controlled prospective study and further clinical experience. J Urol 153(1):47–52. doi:10.1097/00005392-199501000-00019

    Article  CAS  PubMed  Google Scholar 

  14. Skinner DG, Daniels JR, Russell CA, Lieskovsky G, Boyd SD, Krailo M, Groshen S (1990) Adjuvant chemotherapy following cystectomy benefits patients with deeply invasive bladder cancer. Semin Urol 8(4):279–284

    CAS  PubMed  Google Scholar 

  15. Leow JJ, Martin-Doyle W, Rajagopal PS, Patel CG, Anderson EM, Rothman AT, Cote RJ, Urun Y, Chang SL, Choueiri TK, Bellmunt J (2014) Adjuvant chemotherapy for invasive bladder cancer: a 2013 updated systematic review and meta-analysis of randomized trials. Eur Urol 66(1):42–54. doi:10.1016/j.eururo.2013.08.033

    Article  CAS  PubMed  Google Scholar 

  16. Sternberg CN, Skoneczna I, Kerst JM, Albers P, Fossa SD, Agerbaek M, Dumez H, de Santis M, Theodore C, Leahy MG, Chester JD, Verbaeys A, Daugaard G, Wood L, Witjes JA, de Wit R, Geoffrois L, Sengelov L, Thalmann G, Charpentier D, Rolland F, Mignot L, Sundar S, Symonds P, Graham J, Joly F, Marreaud S, Collette L, Sylvester R, European Organisation for R, Treatment of Cancer Genito-Urinary Cancers G, Groupe d’Etude des Tumeurs U, National Cancer Research Institute Bladder Cancer Study G, National Cancer Institute of Canada Clinical Trials G, German Association of Urologic O (2015) Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3–pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial. Lancet Oncol 16(1):76–86. doi:10.1016/S1470-2045(14)71160-X

    Article  PubMed  Google Scholar 

  17. Edge SB, Compton CC (2010) The American joint committee on cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 17(6):1471–1474. doi:10.1245/s10434-010-0985-4

    Article  PubMed  Google Scholar 

  18. Harshman LC, Werner L, Wong Y, Yu EY, Alva Ajjai Shivaram, Crabb Simon J, Powles Thomas, Rosenberg Jonathan E, Baniel Jack, Vaishampayan Ulka N, Berthold Dominik R, Ladoire Sylvain, Hussain Syed A, Milowsky Matthew I, Agarwal Neeraj, Necchi Andrea, Pal Sumanta Kumar, Recine Federica, Bellmunt J, Galsky MD (2015) Adjuvant chemotherapy for residual disease after neoadjuvant chemotherapy for muscle invasive urothelial cancer (MIUC). J Clin Oncol 33:4524

    Google Scholar 

  19. Millikan R, Dinney C, Swanson D, Sweeney P, Ro JY, Smith TL, Williams D, Logothetis C (2001) Integrated therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC. J Clin Oncol 19(20):4005–4013

    CAS  PubMed  Google Scholar 

  20. Lehmann J, Franzaring L, Thüroff J, Wellek S, Stöckle M (2006) Complete long-term survival data from a trial of adjuvant chemotherapy vs. control after radical cystectomy for locally advanced bladder cancer. BJU Int 97(1):42–47

    Article  PubMed  Google Scholar 

  21. Paz-Ares L, Solsona E, Esteban E, Saez A, Gonzalez-Larriba J, Anton A, Hevia M, de la Rosa F, Guillem V, Bellmunt J (2010) Randomized phase III trial comparing adjuvant paclitaxel/gemcitabine/cisplatin (PGC) to observation in patients with resected invasive bladder cancer: results of the spanish oncology genitourinary group (SOGUG) 99/01 study. In: ASCO annual meeting proceedings, vol 28(18_suppl), p LBA4518

  22. Cognetti F, Ruggeri E, Felici A, Gallucci M, Muto G, Pollera C, Massidda B, Rubagotti A, Giannarelli D, Boccardo F (2012) Adjuvant chemotherapy with cisplatin and gemcitabine versus chemotherapy at relapse in patients with muscle-invasive bladder cancer submitted to radical cystectomy: an Italian, multicenter, randomized phase III trial. Ann Oncol 23(3):695–700

    Article  CAS  PubMed  Google Scholar 

  23. Studer U, Bacchi M, Biedermann C, Jaeger P, Kraft R, Mazzucchelli L, Markwalder R, Senn E, Sonntag R (1994) Adjuvant cisplatin chemotherapy following cystectomy for bladder cancer: results of a prospective randomized trial. J Urol 152(1):81–84

    CAS  PubMed  Google Scholar 

  24. Otto T, Goebell P, Rübben H (2003) Perioperative chemotherapy in advanced bladder cancer-part II: adjuvant treatment. Oncol Res Treat 26(5):484–488

    Article  CAS  Google Scholar 

  25. Bono A, Benvenuti C, Gibba A, Guazzeri S, Cosciani-Cunico S, Anselmo G, Martini E, Parma G, Ferrari P, Viggiano G (1997) Adjuvant chemotherapy in locally advanced bladder cancer. Final analysis of a controlled multicentre study. Acta Urol Ital 11:5–8

    Google Scholar 

  26. Siefker-Radtke AO, Dinney CP, Shen Y, Williams DL, Kamat AM, Grossman HB, Millikan RE (2013) A phase 2 clinical trial of sequential neoadjuvant chemotherapy with ifosfamide, doxorubicin, and gemcitabine followed by cisplatin, gemcitabine, and ifosfamide in locally advanced urothelial cancer: final results. Cancer 119(3):540–547. doi:10.1002/cncr.27751

    Article  CAS  PubMed  Google Scholar 

  27. Milowsky MI, Nanus DM, Maluf FC, Mironov S, Shi W, Iasonos A, Riches J, Regazzi A, Bajorin DF (2009) Final results of sequential doxorubicin plus gemcitabine and ifosfamide, paclitaxel, and cisplatin chemotherapy in patients with metastatic or locally advanced transitional cell carcinoma of the urothelium. J Clin Oncol 27(25):4062–4067. doi:10.1200/JCO.2008.21.2241

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Sonpavde G, Pond GR, Choueiri TK, Mullane S, Niegisch G, Albers P, Necchi A, Di Lorenzo G, Buonerba C, Rozzi A, Matsumoto K, Lee JL, Kitamura H, Kume H, Bellmunt J (2015) Single-agent taxane versus taxane-containing combination chemotherapy as salvage therapy for advanced urothelial carcinoma. Eur Urol. doi:10.1016/j.eururo.2015.07.042

    Google Scholar 

Download references

Authors’ contribution

Kamran Zargar-Shoshtari was involved in protocol/project development, data collection, data analysis and manuscript writing. Michael Kongnyuy took part in data collection. Pranav Sharma and Philippe E Spiess were involved in protocol/project development and manuscript editing. Mayer N Fishman took part in manuscript writing. Scott M. Gilbert, Michael A Poch, Julio M Powsang and Jingsong Zhang were involved in manuscript editing. Wade J Sexton took part in protocol/project development, data analysis and manuscript editing.

Author information

Authors and Affiliations

  1. Department of Genitourinary Oncology, Moffitt Cancer Center, 12902 Magnolia Dr, Tampa, FL, 33612, USA

    Kamran Zargar-Shoshtari, Michael Kongnyuy, Pranav Sharma, Mayer N. Fishman, Scott M. Gilbert, Michael A. Poch, Julio M. Pow-Sang, Philippe E. Spiess, Jingsong Zhang & Wade J. Sexton

Authors
  1. Kamran Zargar-Shoshtari
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael Kongnyuy
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Pranav Sharma
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mayer N. Fishman
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Scott M. Gilbert
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Michael A. Poch
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Julio M. Pow-Sang
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Philippe E. Spiess
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Jingsong Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Wade J. Sexton
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Wade J. Sexton.

Ethics declarations

Conflict of interest

None to declare.

Ethical statement

IRB’s approval was obtained for the use of patients’ data for the purpose of this study. All patients are informed at the time of surgical consent that their clinical data may be used for research purposes.

Electronic supplementary material

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zargar-Shoshtari, K., Kongnyuy, M., Sharma, P. et al. Clinical role of additional adjuvant chemotherapy in patients with locally advanced urothelial carcinoma following neoadjuvant chemotherapy and cystectomy. World J Urol 34, 1567–1573 (2016). https://doi.org/10.1007/s00345-016-1825-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00345-016-1825-3

Keywords

Search

Navigation